ERBB2 and ductal breast carcinoma in situ: This case challenges the conventional diagnostic and therapeutic paradigm for PD‐DCIS and compellingly highlights the potential for the HER2‐positive MPD‐DCIS phenotype to demonstrate virulent, metastatic potential.